1.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label,...
by Zhou, Caicun, Prof
The lancet oncology, 2011, Vol.12 (8), p.735-742
2.
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label...
by Wu, Yi-Long, Prof
The lancet oncology, 2014, Vol.15 (2), p.213-222
3.
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and L...
by Yang, James C-H, Prof
The lancet oncology, 2015, Vol.16 (7), p.830-838
4.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-...
by Miller, Vincent A, Prof
The lancet oncology, 2012, Vol.13 (5), p.528-538
5.
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
by Crinò, Lucio, Prof
The lancet oncology, 2010, Vol.11 (8), p.733-740
6.
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
by Wu, Yi-Long, Prof
The lancet oncology, 2013, Vol.14 (8), p.777-786
7.
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
by Shi, Yuankai, MD
The lancet oncology, 2013, Vol.14 (10), p.953-961
8.
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
by Herbst, Roy S, Prof
The lancet oncology, 2010, Vol.11 (7), p.619-626
9.
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind random...
by Zhang, Li, Prof
The lancet oncology, 2012, Vol.13 (5), p.466-475
10.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phas...
by Yang, James Chih-Hsin, Prof
The lancet oncology, 2015, Vol.16 (2), p.141-151
11.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
by Soria, Jean-Charles, Prof
The lancet oncology, 2015, Vol.16 (8), p.897-907
